Agreement was also reached relative to the lower risk of hypoglycemia, weight control and simplicity of administration of FRCs, potentially improving adherence, while it was highly debated whether FRCs would mitigate side effects of GLP-1 RA, and the corresponding statement was considered uncertain [39, 40]. The gene discussed is GLP1R; the disease is Hypoglycemia.